Patents Assigned to Solis Therapeutics, Inc.
  • Methods of enhancing antigen-specific T cell responses
    Patent number: 5738852
    Abstract: Recombinant polynucleotides are provided that confer at least partial immunity on an individual to an infectious intracellular pathogenic agent. The recombinant polynucleotides encode a costimulatory factor and/or a target antigen polypeptide. The immune response that confers the immunity results from the expression of both polypeptides in an antigen presenting cell in the individual. The immunity is to the pathogenic agent that naturally encodes the target antigen polypeptide.
    Type: Grant
    Filed: July 29, 1996
    Date of Patent: April 14, 1998
    Assignee: Solis Therapeutics, Inc.
    Inventors: William S. Robinson, Keting Chu